Measurement of Tau Filament Fragmentation Provides Insights into Prion-like Spreading. by Kundel, Franziska et al.
Measurement of Tau Filament Fragmentation Provides Insights into
Prion-like Spreading
Franziska Kundel,† Liu Hong,†,# Benjamin Falcon,‡ William A. McEwan,‡,∇ Thomas C. T. Michaels,†,§
Georg Meisl,† Noemi Esteras,∥ Andrey Y. Abramov,∥ Tuomas J. P. Knowles,*,† Michel Goedert,*,‡
and David Klenerman*,†,⊥
†Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom
‡MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, United Kingdom
§Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts 02138, United States
∥Department of Molecular Neuroscience, UCL Institute of Neurology, London WC1N 3BG, United Kingdom
⊥UK Dementia Research Institute, University of Cambridge, Cambridge CB2 0XY, United Kingdom
*S Supporting Information
ABSTRACT: The ordered assembly of amyloidogenic proteins
causes a wide spectrum of common neurodegenerative diseases,
including Alzheimer’s and Parkinson’s diseases. These diseases
share common features with prion diseases, in which misfolded
proteins can self-replicate and transmit disease across different
hosts. Deciphering the molecular mechanisms that underlie the
amplification of aggregates is fundamental for understanding how
pathological deposits can spread through the brain and drive
disease. Here, we used single-molecule microscopy to study the
assembly and replication of tau at the single aggregate level. We
found that tau aggregates have an intrinsic ability to amplify by
filament fragmentation, and determined the doubling times for
this replication process by kinetic modeling. We then simulated the spreading time for aggregates through the brain and found
this to be in good agreement with both the observed time frame for spreading of pathological tau deposits in Alzheimer’s disease
and in experimental models of tauopathies. With this work we begin to understand the physical parameters that govern the
spreading rates of tau and other amyloids through the human brain.
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For many years, cell autonomous mechanisms were believedto account for human neurodegenerative diseases.
However, mounting evidence suggests that the protein
assemblies, which are involved in various neurodegenerative
diseases, including aggregated tau, are capable of self-sustaining
amplification.1 The latter is believed to enable the propagation
of pathological assemblies along connected brain cells, resulting
in progression from restricted areas to large numbers of brain
regions. This phenomenon is commonly referred to as prion-
like spreading. According to the prion hypothesis, upon entry
into the cytoplasm of cells, tau assemblies can seed the
aggregation of native monomers, thereby initiating the
formation of additional aggregates, which can be released and
spread to neighboring cells.2,3 Synthetic tau filaments made
from recombinant protein as well as filamentous material
extracted from tau mouse models or Alzheimer’s disease (AD)
brains have been shown to act as seeds in various model
systems and initiate the spreading of tau pathology.4
On a molecular level, to achieve propagation of protein
aggregates through the brain, an amplification of seeds is
required. This requires secondary aggregation processes, by
which new seeds are produced through the fragmentation of
filaments and/or new assemblies form on the surface of existing
filaments.5 For prion diseases, amplification appears to occur
predominantly through fragmentation.6,7 Thus, an inverse
correlation between the stability of prions and their infectivity
has been described.7−9 The mechanisms of amplification of tau
seeds are less well studied. In experimental studies of tau
transmission or propagation in cells or animal models, seed
material is often amplified artificially by sonication before
administration to the model system to increase the efficiency of
templated seeding. Here, we set out to quantify the intrinsic
ability of tau to amplify in order to gain insights into the key
mechanisms governing prion-like spreading of tau in vivo. For
this purpose, we characterized the aggregation kinetics of
unlabeled full-length wild-type and mutant P301S tau using the
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recently developed single-molecule technique SAVE (Single
Aggregate Visualization by Enhancement) imaging.10
■ RESULTS AND DISCUSSION
As the kinetic rates for the elongation and fragmentation of
amyloid proteins can be derived from the length distributions
of filaments during aggregation,11,12 we employed SAVE
imaging to follow the evolution of fibrillar tau aggregates. In
more detail, wild-type and P301S tau (both 0N4R isoform)
were aggregated in vitro using heparin as an inducer; at regular
time points, aliquots of these aggregation reactions were mixed
with the luminescent conjugated oligothiophene pFTAA13 and
imaged on a total internal reflection fluorescence (TIRF)
microscope (see scheme in Figure 1a). As pFTAA has a high
affinity for tau aggregates14 and becomes highly fluorescent
upon binding, we could readily detect the evolution of single
tau fibrils after the induction of aggregation using this approach
(see Figure 1b-i for representative images). It should be noted
that our method was not able to detect small fibrillar species
(<100 nm), either due to the reduced number of dye binding
sites or reduced binding of small aggregates to the glass surface,
and therefore fewer species were visible on our images at the
early and late time-points.
In order to obtain quantitative mechanistic insights from our
SAVE images, we extracted the average lengths of fibrillar
aggregates present at each time point and plotted these as a
function of aggregation time. Aggregates smaller than the
diffraction limit were counted as fibrils with the length of 1
pixel (204 nm). This revealed two stages of aggregation for
both wild-type and mutant tau: first a relatively short stage
(<200 h for the wild-type protein and <24 h for the P301S
mutant) dominated by an increase of the average fibril length
by elongation, and a long second phase during which the
average fibril length decreased (see Figure 1b-ii). Wild-type tau
aggregated slowly into straight fibrils with a maximum apparent
length of 900 to 1,000 nm. By contrast, mutant P301S tau
elongated markedly faster into long fibrils with curly
appearance, reaching an apparent average length of 2,000 to
3,000 nm. In the late stage of aggregation, fibrils from both
protein variants decreased in length over time and this effect
Figure 1. Tau aggregation is a two stage process of elongation and fragmentation. (a) Observing the aggregation of full length tau by SAVE imaging.
Wild-type and P301S tau (0N4R) were incubated under aggregating conditions for up to 2 months. At regular time points, aliquots of the reaction
mixtures were stained with pFTAA, adsorbed onto a glass cover slide and imaged on a TIRF microscope. (b) (i) Representative images of fibrils
during midelongation phase, at maximum length and at the end point. Scale bar: 15 μm. Inset: 3-fold magnification of boxed areas. Scale bar: 2.5 μm.
(ii) The apparent average length of fibrils was analyzed and plotted as a function of time. To account for the diffraction limited resolution, the
“apparent” average length was plotted whereby diffraction limited spots are counted as fibrils with a length of 1 pixel (204 nm). N = 3 (3 different
batches of protein, each in triplicates). Error bars: SEM. Solid lines: fit to fragmentation model. (c) Representative electron micrographs of the 2 μM
P301S aggregation reaction after 24 h and after 672 h. Scale bar: 500 nm. Dotted areas were magnified and shown on the right. Scale bar: 100 nm.
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was more apparent for P301S tau than for wild-type tau. At 10
μM aggregation concentration, wild-type fibrils decreased in
size from around 900 nm at maximum to around 570 nm at the
last measurement and mutant fibrils decreased from around
3000 nm to around 1300 nm. A comparison of the size
histograms of P301S tau fibrils at the end of the elongation
phase (24 h/1 day) with late fibrils (672 h/28 days) showed a
redistribution of long fibrils toward small fibrils with a length
less than 400 nm (Supporting Figure 1a). To corroborate this
finding and to get an estimate of the fragment lengths by a
nondiffraction limited method, transmission electron micros-
copy (TEM) was performed on P301S tau aggregates after 1
day and 28 days of aggregation (see representative electron
micrographs in Figure 1c). The length histograms obtained
from these images confirmed an increase of small fragments
with a length of less than 100 nm after 28 days (Supporting
Figure 1b). Taken together, this data shows that tau undergoes
slow spontaneous fibril fragmentation, leading to a buildup of
small fibrillar fragments over long periods of time. No
proteolysis of tau was observed over the course of aggregation
studied here, indicating that the protein stayed intact (see
Supporting Figure 2).
Next, the experimentally determined average fibril lengths
were fitted to a kinetic model of filamentous aggregation. Only
a kinetic model describing aggregation as a nucleation-
elongation mechanism with fibril fragmentation15,16 (solid
lines in Figure 1b-ii; kinetic model Figure 2a) was able to
fully reproduce the data (see Supporting Information for
details). By contrast, a model in which the fibrils self-replicate
via secondary nucleation and do not fragment was unable to
reproduce the data (see supporting Figure 3). The rate
constants obtained from the fits are shown in Figure 2b. Both
the elongation and fragmentation kinetics of tau determine the
efficiency by which new fibrillar seeds are formed from existing
aggregates. Here, we found that P301S tau has a 64 times faster
elongation rate compared to wild type tau, possibly due to
P301S tau existing in a more favorable conformation for
addition to fibril ends than wild-type tau. The fragmentation
rates of both protein variants are the same within experimental
error. The primary nucleation rate constant and the critical
nucleus size do not influence the amplification rate of existing
aggregates and are therefore not relevant for aggregate
spreading in vivo.
Importantly, it was shown that the phenotype of different
yeast prion strains can be predicted by a simple analytical
model which takes into account the availability of monomeric
protein, the rate of cell division, and the elongation and
fragmentation rates of the different prion strains.8 Here, we
employ a similar model based on the experimentally
determined rates for tau fibril growth and fragmentation to
obtain estimates for the rate of prion-like replication of tau in
vivo (see Figure 3a), since recombinant tau fibrils similar to the
ones studied here have previously been shown to seed
endogenous tau in recipient cells3,17−20 and in PS19 mice
(transgenic for 1N4R P301S tau).21 If one assumes that the
elongation and fragmentation rates are unaltered in vivo, we can
derive the doubling time of tau aggregates from stochastic
Figure 2. Kinetic model. (a) Schematic of microscopic steps during tau aggregation and corresponding rate constants. (b) Rate constants obtained
from fits. Km is the critical concentration for saturated elongation; nc is the critical nucleus size. It is assumed that only the nucleation step is heparin
dependent. Errors are allowed relative deviation.
Figure 3. Simulations of tau fibril replication. (a) Hypothetical
mechanism for tau fibril amplification and spreading in tissues. (b,c)
Simulations of stochastic fibril amplification for wild-type (green) and
P301S tau (blue) aggregates (b) in the htau P301S mouse model or
(c) in humans. On the left, representative simulations are shown for
each condition; average amplification times of tau aggregates are
shown on the right. For each condition, 100 independent simulations
were performed to obtain a reliable amplification time.
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simulations of fibril growth and fragmentation. Notably, these
processes are dependent on the availability of free monomer
which can be added onto fibril ends during elongation. In the
htau P301S mouse model overexpressing human P301S tau, we
estimate the cytosolic human tau concentration to be ≈6 μM,
assuming negligible binding of human tau to microtubules in
the presence of mouse tau (see Supporting Figure 4). As shown
in our simulations, fibril amplification is efficient at this
concentration of free monomer (Figure 3b). On average, the
doubling time t2 for a tau seed is given by
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where m is the concentration of monomer, k+ is the elongation
rate, kf is the fragmentation rate, and Km is the critical
concentration for saturated elongation.15 Under these con-
ditions, we obtain a doubling time of 8 days for wild-type tau
and 1.7 days for P301S tau. In order to put these doubling
times into the context of tau propagation in a mouse brain,
containing around 70 million neurons,22 we calculated the time
it would take to obtain one aggregate per cell (i.e., 70 million
aggregates). According to our simple model, this would take
around 7 months for wild-type tau and 1.5 months for P301S
tau, values which are within an order of magnitude agreement
of the experimentally observed life span of transgenic mice.23
In human neuronal cells, the cytosolic concentration of
monomeric tau is markedly lower as the protein is expressed at
endogenous levels and binds with nanomolar affinity to
microtubules.24,25 Therefore, when we lowered the cytosolic
tau concentration in our simulations to 100 nM, the doubling
times for wild-type and P301S tau aggregates increased
distinctly to 38 days and 5 days, respectively (see Figure 3c).
Based on these doubling times and the larger number of cells in
a human brain (∼90 billion cells26), we obtain estimates of
approximately 4 years for the spreading of wild-type tau
through the brain or approximately 6 months for the
frontotemporal dementia (FTD) associated mutant P301S
tau. By comparison, the age of onset for sporadic AD is around
65,27 while early onset FTD in individuals with the P301S
mutation starts in their 20s or 30s.28,29 The time between
diagnosis and death is similar in both cases with typically 8−10
years.
It is important to note that the spreading of aggregates in vivo
is dependent on many factors such as the efficiency of uptake,
the rate of aggregate clearance, the release of new seeds from
the cytosol, and so forth. These and other factors likely reduce
the spreading efficiency, i.e., the fraction of aggregates which
successfully enter a cell and amplify. Thus, seeding efficiencies
in vitro, where recombinant aggregates are added to cultured
cells, are usually much lower than 100%.17,30 However, due to
the exponential nature of fibril replication, our model is
relatively insensitive to changes in spreading efficiencies, with
estimated spreading times remaining within an order of
magnitude of a human life span even at very low spreading
efficiencies such as 0.0001% (see Supporting Table 1).
We have recently also measured the elongation and
fragmentation rate for murine PrP and human α-synuclein31
under similar experimental conditions (see Supporting Table
2), and these are plotted in Figure 4 for comparison. Since the
doubling time depends on the product of the elongation and
fragmentation rate, it is possible to have a slow fragmentation
rate but a fast elongation rate for efficient aggregate
amplification as is the case for P301S tau. Murine PrP has
high values of both rate constants and is therefore predicted to
amplify and hence spread much faster than the other proteins.
Both wild-type tau and α-synuclein are predicted to amplify
more slowly and appear to have doubling times close to the
limit for the disease to occur in the human lifetime (Figure 4,
gray area). Intriguingly, these values seem to correlate with the
time of disease progression in the respective diseases, with the
most common prion disease Creutzfeldt−Jakob disease having
the shortest survival time of a few months to 2 years,32 followed
by tauopathies such as AD and FTD with a survival time of
around 10 years27−29 and Parkinson’s disease (the most
common α-synucleinopathy) where disease worsens over long
periods of time (10−20 years).33
Based on our findings, we suggest that the exponential
amplification of aggregates by fragmentation is the basis for
prion-like spreading in tauopathies such as AD and could play
an important role in other neurodegenerative conditions. The
exponential phase may be preceded by an initial lag phase
during which the first tau aggregates are formed. Subsequently,
a long silent period would follow, during which tau pathology
slowly spreads but remains undetectable by common staining
protocols. This hypothesis is supported by the recent finding
that abnormal tau is indeed present in subcortical regions in a
large fraction of young asymptomatic individuals.34,35 Fur-
thermore, brain tissue derived from mice transgenic for P301S
tau shows seeding activity long before pathological tau deposits
can be detected by immunohistological staining,36,37 suggesting
that seeds are present well before they can be detected by
common staining protocols. Similarly, in tissue from human AD
subjects at early Braak stages, seeding activity was observed
including cortical regions which lack overt neurofibrillary
pathology.38 If correct, this makes it very hard to study this
process directly due to the long doubling times and modeling
enables extrapolation from experiments performed under
conditions where seeding is more favorable and can hence be
more easily measured. While not fully quantitative, our simple
model provides insights into the key factors that will likely
affect spreading rates. Higher expression of tau in specific cells
would lead to faster doubling times in these cells while
conversely efficient removal of aggregates by the cell would
extend the doubling time. These factors in combination could
provide a simple explanation for why certain cells are more
Figure 4. Elongation and fragmentation rates for murine PrP, tau, and
α-synuclein. Elongation and fragmentation rates of several disease
associated proteins. The conditions used to determine these rate
constants are shown in Supporting Table 2. The shaded area
represents the minimum product of rate constants that would yield
90 billion aggregates in 100 years at a protein concentration of 100
nM.
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susceptible to aggregate formation. Furthermore, different tau
aggregate strains may have different fragmentation or
elongation rates and thus different doubling times as is the
case for prion strains,8 which could account for the varying
rates of disease progression in different tauopathies and
patients.27−29 It is worth noting that tau aggregates present in
cells will continue to grow and fragment with time resulting in a
loss of function and several aggregates being present in a cell,
which could be toxic to cells and ultimately contribute to
neuronal death. Cell division will reduce the number of
aggregates, offering a possible explanation for why spreading
occurs via connected neurons since they do not divide.
In summary, we have quantified the growth and amplification
processes of full length tau and found that it can sustain a slow
prion-like spreading mechanism. Further, we have developed a
simple model that is able to make semiquantitative predictions
about the replication of tau aggregates in the brain, which are in
good agreement with experimental observations. Finally,
extending the doubling time by reducing the rate of elongation
or fragmentation may be a valid strategy for the treatment of
tauopathies.
■ METHODS
Tau Purification. Human 0N4R tau and human 0N4R P301S tau
were expressed as previously described.19,29 Induced cells were
cultured for 3−4 h at 37 °C, then harvested by centrifugation, and
finally resuspended in buffer A (50 mM MES, 0.1 mM PMSF, 2 mM
TCEP, pH 6.5), containing one EDTA-free complete protease
inhibitor cocktail tablet per liter of culture. The cells were lysed by
sonication (1 × 1.5 min, 5 s on, 10 s off, 40% amplitude), and the
soluble fraction was cleared from cell debris by centrifugation at 4 °C,
15 000g (JA-20 rotor, Beckman Coulter). The cleared lysate was then
filtered through a 0.45 μM syringe driven filter and loaded onto a
HiTrap Capto S column (5 mL, GE Healthcare) previously
equilibrated with buffer A. After any unbound proteins were removed
from the column by washing with 10 column volumes of buffer A, tau
was eluted using a linear gradient from 0 to 50% buffer B (buffer A + 1
M NaCl) over 10 column volumes. Fractions containing tau protein
were then pooled and precipitated with 20% ammonium sulfate at 4
°C for 1h and the precipitate collected by centrifugation at 4 °C,
15,000 g (JA-20 rotor, Beckman Coulter). This pellet was either stored
at −20 °C overnight or used directly for the next purification step. Tau
was further purified by size-exclusion chromatography on a Superdex
200 Increase 10/300 GL size exclusion column (GE Healthcare Life
Sciences), previously equilibrated with 1x SSPE and 1 mM TCEP. The
fractions collected were analyzed by SDS-PAGE, and those showing
the purest bands corresponding to tau were pooled. The protein
concentration was determined by measuring its absorbance at 280 nm
on a Nanodrop 2000 using an extinction coefficient of 7450 M−1 cm−1
and by BCA assay. Aliquots were frozen in liquid nitrogen and stored
at −80 °C.
TIRF Microscope. The samples were imaged using a home-built
total internal reflection fluorescence microscope. The total internal
reflection mode restricts the fluorescence illumination to within 200
nm from the sample slide. A 488 nm laser (Cobolt MLD) was aligned
and directed parallel to the optical axis at the edge of a 1.49 NA TIRF
objective (APON60XO TIRF, Olympus), mounted on an inverted
Nikon Eclipse Ti microscope. Fluorescence was collected by the same
objective and separated from the returning TIRF beam by a dichroic
mirror (Di01-R405/488/532/635, Semrock), and passed through an
emission filters (FF03-525/50-25, Semrock). The control of the
hardware was performed using custom-written scripts (bean-shell) for
MicroManager (NIH). The images were recorded on an EMCCD
camera (Evolve 512 Delta, Photometrics) operating in frame transfer
mode (EMGain of 4.4 e−/ADU and 250 ADU/photon). Each pixel
was 204 nm in length. Images were recorded for 30 frames with an
exposure time of 50 ms and averaged using ImageJ (NIH) software.
Sample Preparation for TIRF Imaging. Borosilicate glass
coverslips (VWR international, Ø 50 mm) were cleaned using an
argon plasma cleaner (PDC-002, Harrick Plasma) for 30 min to
remove any fluorescent residues. Multiwell slide chambers (Cultur-
eWell chambered cover glass 50 well, Grace Bio-Laboratories) were
separated from the original cover glass and affixed to the cleaned cover
slides. To stain aggregates for imaging, samples were diluted into 30
nM pFTAA to a final protein concentration of 50 nM tau. Then 10 μL
of each sample was adsorbed to the cover slides for 15 min before
imaging.
Analyzing Number and Length of Aggregates. To analyze the
number and length of tau aggregates, a Hessian based filament
detection algorithm was employed as described by Salji et al.39
Electron Microscopy. Samples were placed on glow-discharged
400 meshed Formvar/carbon film-coated copper grids (Sigma-
Aldrich) for 3 min and stained with uranyl acetate. Images were
taken on a Philips Spirit transmission electron microscope at a
magnification of 16 000.
Model. In order to explain the concentration dependent
aggregation of tau proteins, we propose a three-step mechanism:
nucleation, saturated elongation and fragmentation, as shown in Figure
2a. Here, we need to take the saturation effect into consideration, since
for wild-type tau and P301S tau the maximal average fibril length
under 2 μM and 10 μM conditions varies by a factor of less than 1.4
times, in contrast to the prediction of 2.2 times for simple first order
elongation.40 This is a clear sign that monomer saturation needs to be
included.
Accordingly, the following kinetic equation can be used to quantify
the time dependent fiber length distribution of tau fibrils,
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where [Fj](t) (j ≥ nc) is the concentration of tau fibrils constituted by j
monomers, m(t) is the concentration of free tau monomers, and mtot =
m(t) + Σj=nc
∞ j[Fj](t) is the total concentration of tau proteins in the
system. kn, ke, and kf are the rate constants governing the primary
nucleation, elongation, and fragmentation of tau fibrils, respectively. nc
is the critical nucleus size for primary nucleation, and Km is the critical
concentration for saturated elongation. With respect to [Fj](t), we can
further introduce Pobs(t) = Σj=nb
∞ [Fj](t) and Mobs(t) = Σj=nb
∞ j·[Fj](t) as
the number P and mass concentration M of tau fibrils which are
observable in our single molecule measurement. The smallest
observable aggregate was defined as an aggregate with a length of
100 nm, corresponding to nb = 340 monomers, calculated from the
mass-per length for full length tau fibrils of around 160 kDa/nm.41
Determining the Spreading Time Based on Stochastic-
Deterministic Combined Simulations. In order to assess the
potential of tau to propagate in a prion-like manner, i.e., by cycles of
seeded growth and amplification, and spread over the whole mouse/
human brain under normal physiological conditions, numerical
investigations were performed on the basis of the elongation-
fragmentation mechanism with kinetic rates given in eq 3,
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with m0 as the initial monomer concentration. Instead of direct
stochastic simulations, which cannot reach a sufficiently large number
of fibrils within an adequate computational time (more than 500 years
on a personal computer), we adopted an alternative efficient algorithm
by combining stochastic and deterministic simulations. In detail,
starting from a single tau fibril of an initial length L0 = 1000 monomers
(≅300 nm) in a cell-like volume (10 μm)3, stochastic simulations
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using a Gillespie algorithm implementation were first performed. Then
we switched to the deterministic ODE solver and continued the
calculation from the end point of stochastic simulations, once there
were enough fibrils generated in the system (fibril mass exceeds 10
million monomers, corresponding to ∼1000 fibrils, in our simulation).
For each case, 100 independent simulations were performed to obtain
a reliable spreading time.
Determining Mouse Tau Concentration by ELISA. Whole
brains from P301S tau transgenic mice or wild-type C57BL/6 mice
were snap frozen, suspended in 10x brain mass of A68 buffer (10 mM
Tris-HCl, pH 7.4, 0.8 M NaCl, 1 mM EGTA, and 10% sucrose) and
homogenized using a hand-held homogenizer (Millipore). Debris was
pelleted by centrifugation at 21 000g for 20 min at 4 °C. The
concentration of tau in homogenates was determined using a sandwich
ELISA approach with HT7 (Life Technologies) as capture antibody
and BR13342 as detection antibody. A standard curve was obtained
using recombinant human P301S tau. To calculate the average brain
concentration of tau, it was assumed that brains had a density of 1.1 g/
mL.
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